Cantor Fitzgerald Forecasts AbbVie FY2025 Earnings

AbbVie Inc. (NYSE:ABBV - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for AbbVie in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the company will earn $11.53 per share for the year. The consensus estimate for AbbVie's current full-year earnings is $10.06 per share.

ABBV has been the subject of a number of other research reports. Piper Sandler Companies reiterated an "overweight" rating and set a $220.00 price target on shares of AbbVie in a research note on Tuesday, December 17th. Morgan Stanley decreased their price target on AbbVie from $231.00 to $224.00 and set an "overweight" rating for the company in a report on Tuesday, November 12th. Wells Fargo & Company raised their price objective on AbbVie to $195.00 and gave the company a "buy" rating in a research note on Tuesday, November 19th. Citigroup reduced their target price on shares of AbbVie from $226.00 to $215.00 and set a "buy" rating for the company in a research note on Tuesday, November 12th. Finally, Leerink Partnrs raised shares of AbbVie from a "hold" rating to a "strong-buy" rating in a research report on Friday, November 22nd. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $205.50.

AbbVie Stock Down 2.0 %

Shares of AbbVie stock traded down $3.42 during trading hours on Wednesday, reaching $169.19. The company's stock had a trading volume of 8,420,917 shares, compared to its average volume of 5,934,413. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65. AbbVie has a one year low of $153.58 and a one year high of $207.32. The company has a market capitalization of $298.98 billion, a P/E ratio of 58.75, a P/E/G ratio of 1.69 and a beta of 0.58. The stock's fifty day simple moving average is $175.75 and its two-hundred day simple moving average is $184.84.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Wednesday, October 30th. The company reported $3.00 earnings per share for the quarter, topping analysts' consensus estimates of $2.92 by $0.08. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. The company had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.28 billion. During the same period in the prior year, the firm earned $2.95 earnings per share. AbbVie's revenue for the quarter was up 3.8% on a year-over-year basis.

Institutional Trading of AbbVie

Several institutional investors and hedge funds have recently modified their holdings of ABBV. Atlanta Consulting Group Advisors LLC purchased a new position in AbbVie in the third quarter worth $999,000. Saturna Capital Corp boosted its holdings in shares of AbbVie by 486.1% in the 3rd quarter. Saturna Capital Corp now owns 676,176 shares of the company's stock worth $133,531,000 after purchasing an additional 560,808 shares in the last quarter. Everence Capital Management Inc. boosted its holdings in shares of AbbVie by 41.3% in the 4th quarter. Everence Capital Management Inc. now owns 53,171 shares of the company's stock worth $9,448,000 after purchasing an additional 15,550 shares in the last quarter. GAMMA Investing LLC increased its position in shares of AbbVie by 9.5% during the 4th quarter. GAMMA Investing LLC now owns 39,453 shares of the company's stock valued at $7,011,000 after purchasing an additional 3,439 shares during the last quarter. Finally, Avior Wealth Management LLC raised its holdings in shares of AbbVie by 23.5% during the 3rd quarter. Avior Wealth Management LLC now owns 56,556 shares of the company's stock valued at $11,169,000 after buying an additional 10,768 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.

Insider Transactions at AbbVie

In related news, SVP Kevin K. Buckbee sold 1,800 shares of AbbVie stock in a transaction on Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the sale, the senior vice president now owns 6,983 shares of the company's stock, valued at approximately $1,202,751.92. This trade represents a 20.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.25% of the company's stock.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be given a dividend of $1.64 per share. The ex-dividend date of this dividend is Wednesday, January 15th. This is a boost from AbbVie's previous quarterly dividend of $1.55. This represents a $6.56 annualized dividend and a dividend yield of 3.88%. AbbVie's dividend payout ratio is currently 227.78%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.